Literature DB >> 17323115

Characteristics and treatment outcome of patients requiring additional intravenous analgesia during extracorporeal shockwave lithotripsy with Dornier Compact Delta Lithotriptor.

Chi-Fai Ng1, Trevor Thompson, David Tolley.   

Abstract

OBJECTIVE: To investigate the effect of additional intravenous analgesia (besides oral analgesic premedication) on the treatment outcome in patients receiving extracorporeal shock wave lithotripsy (SWL) with Dornier Compact- Delta lithotriptor.
METHODOLOGY: Five hundred and twenty adults receiving SWL for solitary urinary stone of size </=10 mm were retrospectively reviewed. They received the same analgesic protocol--oral diclofenac 50 mg as premedication and additional intravenous bolus alfentanil if they experienced discomfort during ESWL. After reviewing the analgesic usage, they were divided into two groups, Group-A--received oral analgesic alone and Group-B--received both oral and additional intravenous analgesia during ESWL. Treatment outcome of the two groups was then compared.
RESULTS: There were 306 patients in Group-A and 214 patients in Group-B. The stone-free rates at 3-month for Group-A and -B were 38.2% and 44.9% respectively (P = 0.100). The re-treatment/auxiliary procedure rates for the Group-A and Group-B were 40.8%/12.7%, and 35.0%/18.2% respectively. The additional use of intravenous analgesia improved the effectiveness quotient by 17.7% [from 0.249 (Group-A) to 0.293(Group-B)].
CONCLUSIONS: The additional use of intravenous analgesia during SWL with Dornier Compact Delta lithotriptor resulted in improvement of effectiveness quotient.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17323115     DOI: 10.1007/s11255-006-9124-3

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  9 in total

Review 1.  Extracorporeal lithotripsy. Update on technology.

Authors:  G K Chow; S B Streem
Journal:  Urol Clin North Am       Date:  2000-05       Impact factor: 2.241

2.  Factors determining analgesic and sedative drug requirements during extracorporeal shock wave lithotripsy.

Authors:  A S Salinas; J Lorenzo-Romero; M Segura; M R Calero; I Hernández-Millán; M Martínez-Martín; J A Virseda
Journal:  Urol Int       Date:  1999       Impact factor: 2.089

3.  Effect of stone motion on in vitro comminution efficiency of Storz Modulith SLX.

Authors:  Robin O Cleveland; Ronald Anglade; Richard K Babayan
Journal:  J Endourol       Date:  2004-09       Impact factor: 2.942

4.  Analgesia for shock wave lithotripsy.

Authors:  John Parkin; Francis X Keeley FX; Anthony G Timoney
Journal:  J Urol       Date:  2002-04       Impact factor: 7.450

5.  Local anesthesia for extracorporeal shock wave lithotripsy: a double-blind, prospective, randomized study.

Authors:  A K Türker; S Ozgen
Journal:  Eur Urol       Date:  2000-03       Impact factor: 20.096

6.  Analgesia in piezoelectric SWL: comparative study of kidney and upper ureter treatments.

Authors:  M Robert; P Lanfrey; G Rey; J Guiter; H Navratil
Journal:  J Endourol       Date:  1999 Jul-Aug       Impact factor: 2.942

7.  Noninvasive anesthesia, analgesia and radiation-free extracorporeal shock wave lithotripsy for stones in the most distal ureter: experience with 165 patients.

Authors:  F R Jermini; H Danuser; A Mattei; F C Burkhard; U E Studer
Journal:  J Urol       Date:  2002-08       Impact factor: 7.450

8.  Comparison of intravenous sedation versus general anesthesia on the efficacy of the Doli 50 lithotriptor.

Authors:  Carsten Sorensen; Paramjit Chandhoke; Michael Moore; Connie Wolf; Ali Sarram
Journal:  J Urol       Date:  2002-07       Impact factor: 7.450

9.  Extracorporeally induced destruction of kidney stones by shock waves.

Authors:  C Chaussy; W Brendel; E Schmiedt
Journal:  Lancet       Date:  1980-12-13       Impact factor: 79.321

  9 in total
  1 in total

1.  A heuristic model of stone comminution in shock wave lithotripsy.

Authors:  Nathan B Smith; Pei Zhong
Journal:  J Acoust Soc Am       Date:  2013-08       Impact factor: 1.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.